ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846
Reader Mode
-A A +A

'3(d)' Effect: The Novartis-Glivec Case

The appeal of the multinational drug major Novartis in the Supreme Court against denial of patent protection to its anti-cancer drug Glivec will decide whether Indian courts uphold a "precautionary principle" with regard to the right to health and life or the demands of intellectual property rights must take priority. Either way, this case will have major ramifications for public health and the ability of sovereign countries to enact laws to protect their citizens.

Subscribers please login to access full text of the article.

New 3 Month Subscription
to Digital Archives at

649for India

$20for overseas users

Get instant access to the complete EPW archives

Subscribe now

Comments

(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top